Cns Pharmaceuticals Inc (NASDAQ: CNSP)’s stock price has dropped by -6.15 in relation to previous closing price of 1.22. Nevertheless, the company has seen a loss of -9.13% in its stock price over the last five trading days. accessnewswire.com reported 2025-05-16 that Cash expected to fund operations into the second half of 2026 Advancing development strategy for lead program TPI 287 to commence Phase 2 study around year end 2025 for treatment of glioblastoma multiforme (GBM) HOUSTON, TX / ACCESS Newswire / May 16, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the first quarter ended March 31, 2025 and provided a corporate update. “Our company remains focused as tightly as ever on neuro-oncology drug development.
Is It Worth Investing in Cns Pharmaceuticals Inc (NASDAQ: CNSP) Right Now?
The 36-month beta value for CNSP is also noteworthy at 0.83. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for CNSP is 5.42M, and at present, short sellers hold a 11.62% of that float. The average trading volume of CNSP on May 23, 2025 was 1.79M shares.
CNSP’s Market Performance
The stock of Cns Pharmaceuticals Inc (CNSP) has seen a -9.13% decrease in the past week, with a 19.92% rise in the past month, and a -64.55% fall in the past quarter. The volatility ratio for the week is 3.69%, and the volatility levels for the past 30 days are at 6.22% for CNSP. The simple moving average for the past 20 days is -1.44% for CNSP’s stock, with a -76.30% simple moving average for the past 200 days.
Analysts’ Opinion of CNSP
Ladenburg Thalmann, on the other hand, stated in their research note that they expect to see CNSP reach a price target of $11. The rating they have provided for CNSP stocks is “Buy” according to the report published on August 24th, 2020.
CNSP Trading at -24.12% from the 50-Day Moving Average
After a stumble in the market that brought CNSP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.86% of loss for the given period.
Volatility was left at 6.22%, however, over the last 30 days, the volatility rate increased by 3.69%, as shares surge +10.10% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -54.74% lower at present.
During the last 5 trading sessions, CNSP fell by -9.13%, which changed the moving average for the period of 200-days by -88.21% in comparison to the 20-day moving average, which settled at $1.1617. In addition, Cns Pharmaceuticals Inc saw -80.98% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CNSP
Current profitability levels for the company are sitting at:
- -4998.33 for the present operating margin
- 0.02 for the gross margin
The net margin for Cns Pharmaceuticals Inc stands at -4972.73. The total capital return value is set at -1.43. Equity return is now at value -477.53, with -202.65 for asset returns.
Based on Cns Pharmaceuticals Inc (CNSP), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -81.47. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -4774.79.
Currently, EBITDA for the company is -14.9 million with net debt to EBITDA at 0.82. When we switch over and look at the enterprise to sales, we see a ratio of -2096.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.93.
Conclusion
In summary, Cns Pharmaceuticals Inc (CNSP) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
